Skip to main content
OpenTrials
Completed

NCT Number: NCT01785901

The Asthma Control Rate Achieved by Budesonide/Formoterol in Clinical Practice in China

This is a multi-centre, cross-sectional study planned to be conducted in China. The study aims to observe about 1500 asthma patients who have already received budesonide/formoterol combination treatment by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Beijing, Beijing Municipality, China

Loading trial locations.

About this study

The asthma control rate achieved by budesonide/formoterol in clinical practice in China.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of asthma at least 6 months;
  • Prescribed with budesonide/formoterol treatment at least 3 months before enrolled;
  • Has used the same maintenance dose of budesonide/formoterol for at least 4 weeks before enrolled.

Exclusion criteria

  • Participation in any clinical study within 3 months;
  • Have COPD history/suspicious COPD;
  • ≥ 10 pack years of smoking history
  • Used any other asthma maintenance medication accompanied with budesonide/formoterol within 3 months before enrolled
  • With asthma exacerbation (defined as asthma symptom deterioration resulting oral/rectal/parenteral GCS medication or emergency room treatment or hospitalisation) within 4 weeks before enrolled

Treatment and study plan

without interventions

Other

without interventions

Primary outcomes

  1. The rate of controlled and partly controlled asthma according to the definition of Global Initiative for Asthma

    Time frame: one day

Secondary outcomes

  1. The rate of completely controlled and well controlled asthma according to Asthma Control Test's score

    Time frame: one day

  2. The average frequency of reliever use in previous week

    Time frame: one day

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Feb 7, 2013
Registry last updated
Aug 19, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.